In addition to the Base Contract, the BARDA Contract also contains various options that are exercisable at BARDA???s discretion and would fund development and supportive activities such as work on pediatric and geriatric formulations of the drug as well as use of Tecovirimat for smallpox prophylaxis; would result in $50 million payment to the Company for FDA approval for extension to 84-month expi